Cancer statistics, 2022

Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal, Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.

Keywords: cancer cases; cancer statistics; death rates; incidence; mortality.

© 2022 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.

References

    1. Yabroff, K. R., Wu, X. C., Negoita, S., Stevens, J., Coyle, L., Zhao, J., Mumphrey, B. J., Jemal, A., Ward, K. C. Association of the COVID-19 Pandemic with Patterns of Statewide Cancer Services. J Natl Cancer Inst. June 28 2021.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Registries Research Data with Delay-Adjustment, Malignant Only, November 2020 Submission (1975-2018) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total U.S., 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2021.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Registries Research Data + Hurricane Katrina Impacted Louisiana Cases, November 2020 Submission (2000-2018) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total U.S., 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2021.
    1. Surveillance Research Program. SEER*Explorer: an interactive website for SEER cancer statistics. National Cancer Institute; 2021. Accessed April 15, 2021.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Limited-Field Data With Delay-Adjustment, 21 Registries, Malignant Only, November 2020 Submission (2000-2018)-Linked To County Attributes-Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2021.
    1. Surveillance Research Program, Statistic Methodology and Applications. DevCan: Probability of Developing or Dying of Cancer Software. Version 6.7.9. National Cancer Institute; 2021.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America Analytic File, 1995-2018, With Race/Ethnicity, Custom File With County, American Cancer Society Facts and Figures Projection Project (which includes data from the Center for Disease Control and Prevention's National Program of Cancer Registries, the Canadian Council of Cancer Registries' Provincial and Territorial Registries, and the National Cancer Institute's SEER Registries, certified by the NAACCR as meeting high-quality incidence data standards for the specified time periods). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2021.
    1. Sherman R, Firth R, Charlton M, et al, eds. Cancer in North America: 2014-2018. Volume One: Combined Cancer Incidence for the United States, Canada and North America. North American Association of Central Cancer Registries, Inc; 2021.
    1. Sherman R, Firth R, Charlton M, et al, eds. Cancer in North America: 2014-2018. Volume Two: Registry-Specific Cancer Incidence in the United States and Canada. North American Association of Central Cancer Registries, Inc; 2021.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All Causes of Death, Total U.S. (1969-2019) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total U.S., 1969-2019 Counties (underlying mortality data provided by the National Center for Health Statistics). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2021.
    1. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97(12 suppl):3133-3275.
    1. Murphy SL, Kochanek KD, Xu J, Heron M. Deaths: Final Data for 2012. National Vital Statistics Reports. Vol 63, No. 9. National Center for Health Statistics; 2015.
    1. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005;103:1457-1467.
    1. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. World Health Organization; 2000.
    1. World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems, 10th revision. Vol I-III. WHO; 2011.
    1. Surveillance Research Program. SEER*Stat software, version 8.3.8. National Cancer Institute; 2020.
    1. Surveillance Research Program. Joinpoint Regression Program, version 4.9.0.1. National Cancer Institute, Statistical Research and Applications Branch; 2021.
    1. Mariotto AB, Zou Z, Johnson CJ, Scoppa S, Weir HK, Huang B. Geographical, racial and socio-economic variation in life expectancy in the US and their impact on cancer relative survival. PLoS One. 2018;13:e0201034.
    1. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94:1537-1545.
    1. Liu B, Zhu L, Zou J, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: part I: spatio-temporal modeling for cancer incidence. Cancer Epidemiol Biomarkers Prev. 2021;30:1620-1626.
    1. Miller KD, Siegel RL, Liu B, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: part II: evaluation of incidence and mortality projection methods. Cancer Epidemiol Biomarkers Prev. Published online August 17, 2021. doi:10.1158/1055-9965.EPI-20-1780
    1. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007;57:30-42.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Populations-Total U.S. (1969-2019) <Katrina/Rita Adjustment>-Linked To County Attributes-Total U.S., 1969-2019 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2020.
    1. DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin. 2019;69:452-467.
    1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-638.
    1. Islami F, Sauer AG, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable factors in the United States. CA Cancer J Clin. 2018;68:31-54.
    1. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
    1. Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. J Natl Cancer Inst. Published online July 8, 2021. doi:10.1093/jnci/djab131
    1. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314:2054-2061.
    1. Moyer VA, US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Registries Research Data With Delay-Adjustment, Malignant Only, November 2020 Submission (2000-2018) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total U.S., 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2021.
    1. US Preventive Services Task Force. Draft Recommendation Statement: Screening for Prostate Cancer. US Preventive Services Task Force; 2017. Accessed September 27, 2017.
    1. Fenton J, Weyrick M, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the US Preventive Services Task Force. Report No. 17-05229-EF-1. Agency for Healthcare Research and Quality (US); 2018.
    1. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319:1901-1913.
    1. Shoag JE, Nyame YA, Gulati R, Etzioni R, Hu JC. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020;382:2465-2468.
    1. Kensler KH, Pernar CH, Mahal BA, et al. Racial and ethnic variation in PSA testing and prostate cancer incidence following the 2012 USPSTF recommendation. J Natl Cancer Inst. 2021;113:719-726.
    1. Auvinen A, Rannikko A, Taari K, et al. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. Eur J Epidemiol. 2017;32:521-527.
    1. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767-1777.
    1. Nordstrom T, Discacciati A, Bergman M, et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021;22:1240-1249.
    1. Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of US trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018;27:1214-1222.
    1. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354-361.
    1. US Preventive Services Task Force. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA. 2017;317:1882-1887.
    1. Haugen BR. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017;123:372-381.
    1. Furuya-Kanamori L, Bell KJL, Clark J, Glasziou P, Doi SAR. Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol. 2016;34:3672-3679.
    1. LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex in US thyroid cancer incidence compared with a meta-analysis of subclinical thyroid cancer rates at autopsy. JAMA Intern Med. 2021;181:1351-1358.
    1. Harris JE. Cigarette smoking among successive birth cohorts of men and women in the United States during 1900-80. J Natl Cancer Inst. 1983;71:473-479.
    1. Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. Increasing lung cancer death rates among young women in southern and midwestern states. J Clin Oncol. 2012;30:2739-2744.
    1. Jemal A, Miller KD, Ma J, et al. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. 2018;378:1999-2009.
    1. Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. Ann Intern Med. 2018;169:684-693.
    1. Siegel DA, Fedewa SA, Henley SJ, Pollack LA, Jemal A. Proportion of never smokers among men and women with lung cancer in 7 US states. JAMA Oncol. 2021;7:302-304.
    1. Redfield RR, Hahn SM, Sharpless NE. Redoubling efforts to help Americans quit smoking-federal initiatives to tackle the country's longest-running epidemic. N Engl J Med. 2020;383:1606-1609.
    1. US Department of Health and Human Services. Smoking Cessation. A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2020.
    1. Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut. 2019;68:2179-2185.
    1. Siegel RL, Miller KD, Jemal A. Colorectal cancer mortality rates in adults aged 20 to 54 years in the United States, 1970-2014. JAMA. 2017;318:572-574.
    1. Chow WH, Shuch B, Linehan WM, Devesa SS. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer. 2013;119:388-394.
    1. Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017;109:djx030.
    1. McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother's cancer. Cancer. 2016;122:2787-2798.
    1. Fiorica JV. The role of topotecan in the treatment of advanced cervical cancer. Gynecol Oncol. 2003;90(3 pt 2):S16-S21.
    1. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005;103:1258-1264.
    1. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol. 2010;37:202-215.
    1. Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186-e193.
    1. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002-1014.
    1. Berk-Krauss J, Stein JA, Weber J, Polsky D, Geller AC. New systematic therapies and trends in cutaneous melanoma deaths among US Whites, 1986-2016. Am J Public Health. 2020;110:731-733.
    1. Rami-Porta R, Call S, Dooms C, et al. Lung cancer staging: a concise update. Eur Respir J. 2018;51:1800190.
    1. Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (Lond). 2018;18(suppl 2):s41-s46.
    1. Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer-recent advances and future perspectives. Int J Cancer. 2016;138:2549-2561.
    1. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924-3933.
    1. Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017;6:196-211.
    1. Liu Y, Colditz GA, Kozower BD, et al. Association of Medicaid expansion under the Patient Protection and Affordable Care Act with non-small cell lung cancer survival. JAMA Oncol. 2020;6:1289-1290.
    1. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States-2010 to 2015. JAMA Oncol. 2017;3:1278-1281.
    1. Fedewa SA, Kazerooni EA, Studts JL, et al. State variation in low-dose computed tomography scanning for lung cancer screening in the United States. J Natl Cancer Inst. 2021;113:1044-1052.
    1. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30:1162-1169.
    1. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:962-970.
    1. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000;283:2975-2978.
    1. Negoita S, Feuer EJ, Mariotto A, et al. Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124:2801-2814.
    1. Jemal A, Culp MB, Ma J, Islami F, Fedewa SA. Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening. J Natl Cancer Inst. 2021;113:64-71.
    1. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175-181.
    1. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-455.
    1. Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med. 2019;123:316-323.
    1. Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14:2191-2199.
    1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-172.
    1. Spencer JC, Brewer NT, Coyne-Beasley T, Trogdon JG, Weinberger M, Wheeler SB. Reducing poverty-related disparities in cervical cancer: the role of HPV vaccination. Cancer Epidemiol Biomarkers Prev. 2021;30:1895-1903.
    1. Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:2819372.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
    1. Saslow D, Andrews KS, Manassaram-Baptiste D, Smith RA, Fontham ETH, American Cancer Society Guideline Development Group. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. 2020;70:274-280.
    1. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70:321-346.
    1. Elam-Evans LD, Yankey D, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:1109-1116.
    1. Smith A, Baines N, Mermon S, et al. Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines. Curr Oncol. 2019;26:80-84.
    1. Loke AY, Kwan ML, Wong YT, Wong AKY. The uptake of human papillomavirus vaccination and its associated factors among adolescents: a systematic review. J Prim Care Community Health. 2017;8:349-362.
    1. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.
    1. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
    1. Bailey ZD, Krieger N, Agenor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389:1453-1463.
    1. Commission on Social Determinants of Health. Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health. World Health Organization; 2008.
    1. Braveman P, Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. Public Health Rep. 2014;129(suppl 2):19-31.
    1. Pinheiro LC, Reshetnyak E, Akinyemiju T, Phillips E, Safford MM. Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study. Cancer. Published online September 3, 2021. doi:10.1002/cncr.33894
    1. Lopez L 3rd, Hart LH 3rd, Katz MH. Racial and ethnic health disparities related to COVID-19. JAMA. 2021;325:719-720.
    1. Lynch EE, Malcoe LH, Laurent SE, Richardson J, Mitchell BC, Meier HCS. The legacy of structural racism: associations between historic redlining, current mortgage lending, and health. SSM Popul Health. 2021;14:100793.
    1. Beyer KMM, Zhou Y, Laud PW, et al. Mortgage lending bias and breast cancer survival among older women in the United States. J Clin Oncol. 2021;39:2749-2757.
    1. Krieger N, Wright E, Chen JT, Waterman PD, Huntley ER, Arcaya M. Cancer stage at diagnosis, historical redlining, and current neighborhood characteristics: breast, cervical, lung, and colorectal cancers, Massachusetts, 2001-2015. Am J Epidemiol. 2020;189:1065-1075.
    1. Annesi CA, Poulson M, Mak KS, et al. The impact of residential racial segregation on non-small cell lung cancer treatment and outcomes. Ann Thorac Surg. Published online May 22, 2021. doi:10.1016/j.athoracsur.2021.04.096
    1. Collin LJ, Gaglioti AH, Beyer KM, et al. Neighborhood-level redlining and lending bias are associated with breast cancer mortality in a large and diverse metropolitan area. Cancer Epidemiol Biomarkers Prev. 2021;30:53-60.
    1. Nelson DE, Mowery P, Asman K, et al. Long-term trends in adolescent and young adult smoking in the United States: metapatterns and implications. Am J Public Health. 2008;98:905-915.
    1. Thrift AP, Gudenkauf FJ. Melanoma incidence among non-Hispanic Whites in all 50 US states from 2001 through 2015. J Natl Cancer Inst. 2020;112:533-539.
    1. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2021-2022. American Cancer Society; 2021.
    1. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases. Human Papillomavirus Vaccination Coverage Among Adolescents (13-17 years). Accessed September 21, 2021.
    1. Nguyen BT, Han X, Jemal A, Drope J. Diet quality, risk factors and access to care among low-income uninsured American adults in states expanding Medicaid vs. states not expanding under the Affordable Care Act. Prev Med. 2016;91:169-171.
    1. Sommers BD, Gawande AA, Baicker K. Health insurance coverage and health-what the recent evidence tells us. N Engl J Med. 2017;377:586-593.
    1. Kantarjian HM, Keating MJ, Freireich EJ. Toward the potential cure of leukemias in the next decade. Cancer. 2018;124:4301-4313.
    1. Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol. 2011;8:417-424.
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2018. National Cancer Institute; 2021.
    1. Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66:182-202.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj